Y-6 Sublingual Tablets for Patients With Acute Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 892 participants.

Also called NCT07040085

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 892 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07040085
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07040085. Randomized; double masking; primary purpose treatment. Start 2025-08-05 (anticipated); primary completion 2027-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Y-6 Sublingual Tablets for Patients With Acute Ischemic Stroke
Condition
Stroke
Intervention (Drug)
Y-6
Intervention (Drug)
Y-6 placebo
Lead sponsor
Beijing Tiantan Hospital (class: other)
Collaborator
Neurodawn Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07040085
Content hash
b40810a1121f2cd7603e66a323e639398bcbc1d9d108f88a00f6764ebc0a739e